Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the full commercial launch of the InSet™ 70 Humeral Stem ("InSet™ 70"). The introduction of the InSet™ 70 represents an expansion of the company's I-Series humeral stem product line, which first launched with the InSet™ 95 humeral stem in 2024.

"The InSet™ 70 complements our broad portfolio of advanced shoulder implant solutions, and we are excited to bring it to market across the United States ahead of schedule," said Rob Ball, CEO of Shoulder Innovations. "SI has a strong history of innovation, and the InSet™ 70 is another example of new technology designed to enhance the quality of care for patients and provide meaningful value to the surgeons who care for them. We look forward to seeing improved patient outcomes and long-term function with this implant."

Indicated for use in both anatomic and reverse shoulder arthroplasty, the InSet™ 70 addresses a broad range of clinical needs, including non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, and correction of functional deformity. In reverse procedures, it is further indicated for irreparable cuff tears with or without arthritis, as well as for revision of other devices when sufficient bone stock remains.

"Featuring the same excellent initial fixation and simple workflow as the longer InSet™ 95, the InSet™ 70 offers the added benefit of bone-sparing utility, making it a compelling offering in the shoulder care space," said Galen Kam, MD. "Essentially, this product affords all the advantages of a larger stem in a smaller, bone-preserving form factor."

"The InSet™ 70 provides my patients with superb humeral fixation within the reverse total shoulder platform, delivering optimized biomechanics and supporting improved shoulder function," said Matthew Pifer, MD.